Ionis Pharmaceuticals, Inc.

This study tests a drug called sapablursen in 50 adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. Participants currently need regular blood removal (phlebotomy) to manage their condition. The goal is to see if the drug can reduce how often …

This study tested the long-term safety and effectiveness of donidalorsen, an injectable drug, in 20 people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Participants received different doses over 64 weeks. The main goal was to check f…

This study tested a drug called olezarsen in 154 adults with high triglycerides (a type of blood fat) and either heart disease or very high triglycerides. Participants received injections of the drug or a placebo for up to 12 months. The main goal was to see if the drug could low…

This Phase 3 study tested a drug called olezarsen in 1,478 people with very high triglycerides (a type of blood fat) and either heart disease or a high risk for it. Participants received either olezarsen or a placebo as a shot under the skin. The main goal was to see if olezarsen…

This Phase 3 trial tested a drug called olezarsen in 617 people with severe hypertriglyceridemia (very high blood fats). Participants received either the drug or a placebo as a shot under the skin. The main goal was to see if olezarsen could lower triglyceride levels more than pl…

This study tested a new medicine called olezarsen in 446 people with very high levels of blood fats (triglycerides). The goal was to see if it could lower these fats more than a placebo. Participants received shots under the skin and followed a healthy diet.

This early-stage trial tested the safety of a new drug called BIIB094 in 62 adults with Parkinson's disease. The drug was given as a spinal injection to see if it is safe and how the body processes it. The study included people with and without certain genetic variations. Results…